Page 1575 - Williams Hematology ( PDFDrive )

1550 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1551

366. Sinisalo M, Aittoniemi J, Kayhty H, et al: Vaccination against infections in chronic lym- 394. Fangazio M, De Paoli L, Rossi D, et al: Predictive markers and driving factors behind
phocytic leukemia. Leuk Lymphoma 44:649–652, 2003. Richter syndrome development. Expert Rev Anticancer Ther 11:433–442, 2011.
367. Sinisalo M, Aittoniemi J, Oivanen P, et al: Response to vaccination against different 395. Rossi D, Spina V, Cerri M, et al: Stereotyped B-cell receptor is an independent risk fac-
types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 114: tor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer
107–110, 2001. Res 15:4415–4422, 2009.
368. Sinisalo M, Vilpo J, Itala M, et al: Antibody response to 7-valent conjugated pneumo- 396. Rossi D, Rasi S, Spina V, et al: Different impact of NOTCH1 and SF3B1 mutations on
coccal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 26:82–87, 2007. the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J
369. Jurlander J, de Nully Brown P, Skov PS, et al: Improved vaccination response during Haematol 158:426–429, 2012.
ranitidine treatment, and increased plasma histamine concentrations, in patients with 397. Lee JN, Giles F, Huh YO, et al: Molecular differences between small and large cells in
B cell chronic lymphocytic leukemia. Leukemia 9:1902–1909, 1995. patients with chronic lymphocytic leukemia. Eur J Haematol 71:235–242, 2003.
370. Tomczyk S, Bennett NM, Stoecker C, et al: Use of 13-valent pneumococcal conju- 398. Papajik T, Myslivecek M, Urbanova R, et al: 2-[18F]fluoro-2-deoxy-D-glucose pos-
gate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged itron emission tomography/computed tomography examination in patients with
≥65 years: Recommendations of the Advisory Committee on Immunization Practices chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma 55:
(ACIP). MMWR Morb Mortal Wkly Rep 63:822–825, 2014. 314–319, 2014.
371. Grohskopf LA, Olsen SJ, Sokolow LZ, et al: Prevention and control of seasonal influenza 399. Noy A, Schoder H, Gonen M, et al: The majority of transformed lymphomas have high
with vaccines: Recommendations of the Advisory Committee on Immunization Prac- standardized uptake values (SUVs) on positron emission tomography (PET) scanning
tices (ACIP)—United States, 2014–15 influenza season. MMWR Morb Mortal Wkly similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 20:508–512, 2009.
Rep 63:691–697, 2014. 400. Tsimberidou AM, Wierda WG, Wen S, et al: Phase I-II clinical trial of oxaliplatin,
372. Bridges CB, Coyne-Beasley T, Advisory Committee on Immunization Practices fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory
(ACIP); et al: Advisory Committee on Immunization Practices recommended immu- chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 13:
nization schedule for adults aged 19 years or older—United States, 2014. MMWR Morb 568–574, 2013.
Mortal Wkly Rep 63:110–112, 2014. 401. Dabaja BS, O’Brien SM, Kantarjian HM, et al: Fractionated cyclophosphamide, vin-
373. Ruzickova S, Pruss A, Odendahl M, et al: Chronic lymphocytic leukemia preceded by cristine, liposomal daunorubicin (DaunoXome), and dexamethasone (hyperCVXD)
cold agglutinin disease: Intraclonal immunoglobulin light-chain diversity in V(H)4–34 regimen in Richter’s syndrome. Leuk Lymphoma 42:329–337, 2001.
expressing single leukemic B cells. Blood 100:3419–3422, 2002. 402. Ohno T, Smir BN, Weisenburger DD, et al: Origin of the Hodgkin/Reed-Sternberg
374. Kipps TJ, Carson DA: Autoantibodies in chronic lymphocytic leukemia and related cells in chronic lymphocytic leukemia with “Hodgkin’s transformation.” Blood 91:
systemic autoimmune diseases. Blood 81:2475–2487, 1993. 1757–1761, 1998.
375. Zent CS, Ding W, Reinalda MS, et al: Autoimmune cytopenia in chronic lymphocytic 403. Ghani AM, Krause JR, Brody JP: Prolymphocytic transformation of chronic lymphocytic
leukemia/small lymphocytic lymphoma: Changes in clinical presentation and progno- leukemia. A report of three cases and review of the literature. Cancer 57:75–80, 1986.
sis. Leuk Lymphoma 50:1261–1268, 2009. 404. Kjeldsberg CR, Marty J: Prolymphocytic transformation of chronic lymphocytic leuke-
376. Quinquenel A, Al Nawakil C, Baran-Marszak F, et al: Old DAT and new data: Positive mia. Cancer 48:2447–2457, 1981.
direct antiglobulin test identifies a subgroup with poor outcome among chronic lym- 405. Parikh SA, Habermann TM, Chaffee KG, et al: Hodgkin transformation of chronic
phocytic leukemia stage A patients. Am J Hematol 90:E5–E8, 2015. lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lym-
377. Shvidel L, Tadmor T, Braester A, et al: Pathogenesis, prevalence, and prognostic signif- phoma. Am J Hematol 90:334–338, 2015.
icance of cytopenias in chronic lymphocytic leukemia (CLL): A retrospective compar- 406. Bacher U, Kern W, Schoch C, et al: Discrimination of chronic lymphocytic leukemia
ative study of 213 patients from a national CLL database of 1,518 cases. Ann Hematol (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic
92:661–667, 2013. markers as investigated by interphase fluorescence in situ hybridization (FISH). Ann
378. Ferrer G, Navarro A, Hodgson K, et al: MicroRNA expression in chronic lymphocytic Hematol 83:349–355, 2004.
leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma 54:2016–2022, 407. Lens D, Coignet LJ, Brito-Babapulle V, et al: B cell prolymphocytic leukaemia (B-PLL)
2013. with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene.
379. Mauro FR, Gentile M, Foa R: Erythropoietin and chronic lymphocytic leukemia. Rev Leukemia 13:873–876, 1999.
Clin Exp Hematol Suppl 1:21–31, 2002. 408. Katayama I, Aiba M, Pechet L, et al: B-lineage prolymphocytic leukemia as a distinct
380. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality clinicopathologic entity. Am J Pathol 99:399–412, 1980.
associated with recombinant erythropoietin and darbepoetin administration for the 409. van der Velden VH, Hoogeveen PG, de Ridder D, et al: B-cell prolymphocytic leuke-
treatment of cancer-associated anemia. JAMA 299:914–924, 2008. mia: A specific subgroup of mantle cell lymphoma. Blood 124:412–419, 2014.
381. Jolliffe E, Romeril K: Eltrombopag for resistant immune thrombocytopenia secondary 410. Tatarczuch M, Blombery P, Seymour JF: De novo B-cell prolymphocytic leukemia with
to chronic lymphocytic leukaemia. Intern Med J 44:697–699, 2014. central nervous system involvement. Leuk Lymphoma 55:1665–1667, 2014.
382. Cobcroft R: Pure red cell aplasia associated with small lymphocytic lymphoma. Br J 411. Pamuk GE, Puyan FO, Unlu E, et al: The first case of de novo B-cell prolymphocytic
Haematol 113:260, 2001. leukemia with central nervous system involvement: Description of an unreported com-
383. Itala M, Kotilainen P, Nikkari S, et al: Pure red cell aplasia caused by B19 parvovirus plication. Leuk Res 33:864–867, 2009.
infection after autologous blood stem cell transplantation in a patient with chronic lym- 412. Matutes E, Brito-Babapulle V, Swansbury J, et al: Clinical and laboratory features of
phocytic leukemia. Leukemia 11:171, 1997. 78 cases of T-prolymphocytic leukemia. Blood 78:3269–3274, 1991.
384. Chikkappa G, Pasquale D, Zarrabi MH, et al: Cyclosporine and prednisone therapy 413. Mourad YA, Taher A, Chehal A, et al: Successful treatment of B-cell prolymphocytic
for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol leukemia with monoclonal anti-CD20 antibody. Ann Hematol 83:319–321, 2004.
41:5–12, 1992. 414. Solh M, Rai KR, Peterson BL, et al: The impact of initial fludarabine therapy on trans-
385. Ding W, Zent CS: Diagnosis and management of autoimmune complications of chronic formation to Richter syndrome or prolymphocytic leukemia in patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma. Clin Adv Hematol Oncol 5: lymphocytic leukemia: Analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma
257–261, 2007. 54:252–254, 2013.
386. Visco C, Barcellini W, Maura F, et al: Autoimmune cytopenias in chronic lymphocytic 415. Catovsky D, Wechsler A, Matutes E, et al: The membrane phenotype of T-prolympho-
leukemia. Am J Hematol 89:1055–1062, 2014. cytic leukaemia. Scand J Haematol 29:398–404, 1982.
387. Visco C, Cortelezzi A, Moretta F, et al: Autoimmune cytopenias in chronic lymphocytic 416. Matutes E, Catovsky D: Similarities between T-cell chronic lymphocytic leukemia and
leukemia at disease presentation in the modern treatment era: Is stage C always stage the small-cell variant of T-prolymphocytic leukemia. Blood 87:3520–3521, 1996.
C? Leuk Lymphoma 55:1261–1265, 2014. 417. Matutes E, Catovsky D: CLL should be used only for the disease with B-cell phenotype.
388. Michallet AS, Rossignol J, Cazin B, et al: Rituximab-cyclophosphamide-dexametha- Leukemia 7:917–918, 1993.
sone combination in management of autoimmune cytopenias associated with chronic 418. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of chronic
lymphocytic leukemia. Leuk Lymphoma 52:1401–1403, 2011. (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative
389. Rossi D, Spina V, Deambrogi C, et al: The genetics of Richter syndrome reveals disease Group. J Clin Pathol 42:567–584, 1989.
heterogeneity and predicts survival after transformation. Blood 117:3391–3401, 2011. 419. Pileri SA, Milani M, Fraternali-Orcioni G, et al: From the R.E.A.L. classification to the
390. Parikh SA, Rabe KG, Call TG, et al: Diffuse large B-cell lymphoma (Richter syndrome) upcoming WHO scheme: A step toward universal categorization of lymphoma entities?
in patients with chronic lymphocytic leukaemia (CLL): A cohort study of newly diag- Ann Oncol 9:607–612, 1998.
nosed patients. Br J Haematol 162:774–782, 2013. 420. Rawstron AC, Green MJ, Kuzmicki A, et al: Monoclonal B lymphocytes with the char-
391. Rossi D, Gaidano G: Richter syndrome: Molecular insights and clinical perspectives. acteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults
Hematol Oncol 27:1–10, 2009. with normal blood counts. Blood 100:635–639, 2002.
392. Mao Z, Quintanilla-Martinez L, Raffeld M, et al: IgVH mutational status and clonal- 421. Goldin LR, Lanasa MC, Slager SL, et al: Common occurrence of monoclonal B-cell
ity analysis of Richter’s transformation: Diffuse large B-cell lymphoma and Hodgkin lymphocytosis among members of high-risk CLL families. Br J Haematol 151:152–158,
lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2010.
2 different pathways of disease evolution. Am J Surg Pathol 31:1605–1614, 2007. 422. Lanasa MC, Weinberg JB: Immunologic aspects of monoclonal B-cell lymphocytosis.
393. Rossi D, Cerri M, Capello D, et al: Biological and clinical risk factors of chronic lym- Immunol Res 49:269–280, 2011.
phocytic leukaemia transformation to Richter syndrome. Br J Haematol 142:202–215, 423. Landgren O, Albitar M, Ma W, et al: B-cell clones as early markers for chronic lympho-
2008. cytic leukemia. N Engl J Med 360:659–667, 2009.

Kaushansky_chapter 92_p1527-1552.indd 1550 9/18/15 10:49 AM